Report says Eli Lilly trial shows retatrutide produces significant weight loss
The triple agonist remains Lilly's next-generation incretin candidate behind tirzepatide.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 5 15:57 ETSource: www.polskieradio.pl
The wire
- 01A report states that an Eli Lilly trial of retatrutide produced significant weight loss; no trial size, dose or endpoint figures accompany the claim.
- 02Retatrutide is the incretin candidate operators and clinicians are watching after tirzepatide, so any late-stage signal shapes expectations for the next obesity launch.
- 03The item carries no verifiable trial details or primary publication, and the findings should be checked against Lilly's own disclosures before being relied on.
From the source
Read at polskieradio.pleli lilly trial shows drug retatrutide produces significant weight loss
